nodes	percent_of_prediction	percent_of_DWPC	metapath
Methamphetamine—SLC22A3—Melphalan—ovarian cancer	0.438	0.909	CbGbCtD
Methamphetamine—L-Phenylalanine—Melphalan—ovarian cancer	0.355	1	CrCrCtD
Methamphetamine—CYP2D6—Vinorelbine—ovarian cancer	0.0317	0.0659	CbGbCtD
Methamphetamine—CYP2D6—Doxorubicin—ovarian cancer	0.012	0.025	CbGbCtD
Methamphetamine—TAAR1—female reproductive system—ovarian cancer	0.00452	0.0509	CbGeAlD
Methamphetamine—SLC18A1—vagina—ovarian cancer	0.00434	0.049	CbGeAlD
Methamphetamine—SLC18A1—lymph node—ovarian cancer	0.00281	0.0317	CbGeAlD
Methamphetamine—SLC18A2—uterine cervix—ovarian cancer	0.00205	0.0231	CbGeAlD
Methamphetamine—SLC22A3—myometrium—ovarian cancer	0.00187	0.0211	CbGeAlD
Methamphetamine—SLC18A2—endometrium—ovarian cancer	0.00185	0.0209	CbGeAlD
Methamphetamine—SLC22A3—embryo—ovarian cancer	0.0018	0.0203	CbGeAlD
Methamphetamine—MAOB—myometrium—ovarian cancer	0.00173	0.0195	CbGeAlD
Methamphetamine—SLC18A2—uterus—ovarian cancer	0.00171	0.0192	CbGeAlD
Methamphetamine—MAOB—embryo—ovarian cancer	0.00167	0.0188	CbGeAlD
Methamphetamine—SLC18A2—female reproductive system—ovarian cancer	0.00153	0.0173	CbGeAlD
Methamphetamine—MAOA—myometrium—ovarian cancer	0.00148	0.0167	CbGeAlD
Methamphetamine—SLC22A3—uterine cervix—ovarian cancer	0.00146	0.0164	CbGeAlD
Methamphetamine—MAOA—embryo—ovarian cancer	0.00142	0.016	CbGeAlD
Methamphetamine—ADRA2C—myometrium—ovarian cancer	0.00142	0.016	CbGeAlD
Methamphetamine—SLC18A2—vagina—ovarian cancer	0.00139	0.0156	CbGeAlD
Methamphetamine—SLC22A5—myometrium—ovarian cancer	0.00136	0.0154	CbGeAlD
Methamphetamine—MAOB—uterine cervix—ovarian cancer	0.00135	0.0152	CbGeAlD
Methamphetamine—SLC22A3—endometrium—ovarian cancer	0.00132	0.0149	CbGeAlD
Methamphetamine—MAOB—decidua—ovarian cancer	0.00129	0.0145	CbGeAlD
Methamphetamine—SLC18A2—testis—ovarian cancer	0.00124	0.014	CbGeAlD
Methamphetamine—SLC22A3—gonad—ovarian cancer	0.00122	0.0138	CbGeAlD
Methamphetamine—MAOB—endometrium—ovarian cancer	0.00122	0.0138	CbGeAlD
Methamphetamine—SLC6A2—decidua—ovarian cancer	0.00119	0.0134	CbGeAlD
Methamphetamine—MAOA—uterine cervix—ovarian cancer	0.00115	0.013	CbGeAlD
Methamphetamine—ADRA2A—myometrium—ovarian cancer	0.00114	0.0128	CbGeAlD
Methamphetamine—MAOB—uterus—ovarian cancer	0.00113	0.0127	CbGeAlD
Methamphetamine—ADRA2C—uterine cervix—ovarian cancer	0.00111	0.0125	CbGeAlD
Methamphetamine—MAOA—decidua—ovarian cancer	0.0011	0.0124	CbGeAlD
Methamphetamine—SLC22A3—female reproductive system—ovarian cancer	0.00109	0.0123	CbGeAlD
Methamphetamine—SLC6A4—female reproductive system—ovarian cancer	0.00106	0.012	CbGeAlD
Methamphetamine—SLC22A5—uterine cervix—ovarian cancer	0.00106	0.012	CbGeAlD
Methamphetamine—ADRA2C—decidua—ovarian cancer	0.00106	0.0119	CbGeAlD
Methamphetamine—SLC6A2—gonad—ovarian cancer	0.00105	0.0118	CbGeAlD
Methamphetamine—MAOA—endometrium—ovarian cancer	0.00104	0.0117	CbGeAlD
Methamphetamine—Pseudoephedrine—IL2—ovarian cancer	0.00103	0.883	CrCbGaD
Methamphetamine—MAOB—female reproductive system—ovarian cancer	0.00101	0.0114	CbGeAlD
Methamphetamine—ADRA2C—endometrium—ovarian cancer	0.001	0.0113	CbGeAlD
Methamphetamine—SLC22A3—female gonad—ovarian cancer	0.000995	0.0112	CbGeAlD
Methamphetamine—SLC22A3—vagina—ovarian cancer	0.000989	0.0111	CbGeAlD
Methamphetamine—MAOA—uterus—ovarian cancer	0.00096	0.0108	CbGeAlD
Methamphetamine—SLC22A5—endometrium—ovarian cancer	0.000959	0.0108	CbGeAlD
Methamphetamine—SLC6A3—testis—ovarian cancer	0.000937	0.0106	CbGeAlD
Methamphetamine—SLC6A2—female reproductive system—ovarian cancer	0.000937	0.0106	CbGeAlD
Methamphetamine—ADRA2C—uterus—ovarian cancer	0.000923	0.0104	CbGeAlD
Methamphetamine—MAOB—female gonad—ovarian cancer	0.00092	0.0104	CbGeAlD
Methamphetamine—MAOB—vagina—ovarian cancer	0.000915	0.0103	CbGeAlD
Methamphetamine—SLC18A2—lymph node—ovarian cancer	0.000898	0.0101	CbGeAlD
Methamphetamine—ADRA2A—uterine cervix—ovarian cancer	0.000884	0.00996	CbGeAlD
Methamphetamine—SLC22A3—testis—ovarian cancer	0.000882	0.00994	CbGeAlD
Methamphetamine—MAOA—female reproductive system—ovarian cancer	0.000863	0.00972	CbGeAlD
Methamphetamine—ADRA2A—decidua—ovarian cancer	0.000842	0.00949	CbGeAlD
Methamphetamine—MAOB—testis—ovarian cancer	0.000816	0.0092	CbGeAlD
Methamphetamine—ADRA2A—endometrium—ovarian cancer	0.000799	0.00901	CbGeAlD
Methamphetamine—SLC22A5—female reproductive system—ovarian cancer	0.000795	0.00896	CbGeAlD
Methamphetamine—MAOA—female gonad—ovarian cancer	0.000785	0.00885	CbGeAlD
Methamphetamine—MAOA—vagina—ovarian cancer	0.00078	0.00879	CbGeAlD
Methamphetamine—SLC6A2—testis—ovarian cancer	0.000756	0.00852	CbGeAlD
Methamphetamine—ADRA2C—female gonad—ovarian cancer	0.000755	0.00851	CbGeAlD
Methamphetamine—ADRA2C—vagina—ovarian cancer	0.00075	0.00846	CbGeAlD
Methamphetamine—ADRA2A—gonad—ovarian cancer	0.000741	0.00835	CbGeAlD
Methamphetamine—ADRA2A—uterus—ovarian cancer	0.000736	0.0083	CbGeAlD
Methamphetamine—SLC22A5—female gonad—ovarian cancer	0.000723	0.00815	CbGeAlD
Methamphetamine—SLC22A5—vagina—ovarian cancer	0.000719	0.0081	CbGeAlD
Methamphetamine—MAOA—testis—ovarian cancer	0.000696	0.00785	CbGeAlD
Methamphetamine—ADRA2C—testis—ovarian cancer	0.00067	0.00755	CbGeAlD
Methamphetamine—ADRA2A—female reproductive system—ovarian cancer	0.000662	0.00746	CbGeAlD
Methamphetamine—SLC22A5—testis—ovarian cancer	0.000641	0.00723	CbGeAlD
Methamphetamine—SLC22A3—lymph node—ovarian cancer	0.000639	0.00721	CbGeAlD
Methamphetamine—ADRA2A—female gonad—ovarian cancer	0.000602	0.00679	CbGeAlD
Methamphetamine—ADRA2A—vagina—ovarian cancer	0.000599	0.00675	CbGeAlD
Methamphetamine—MAOB—lymph node—ovarian cancer	0.000592	0.00667	CbGeAlD
Methamphetamine—Digestion impaired—Chlorambucil—ovarian cancer	0.000574	0.0904	CcSEcCtD
Methamphetamine—SLC6A2—lymph node—ovarian cancer	0.000548	0.00617	CbGeAlD
Methamphetamine—ADRA2A—testis—ovarian cancer	0.000534	0.00602	CbGeAlD
Methamphetamine—CYP2D6—female reproductive system—ovarian cancer	0.000513	0.00578	CbGeAlD
Methamphetamine—MAOA—lymph node—ovarian cancer	0.000505	0.00569	CbGeAlD
Methamphetamine—Digestion impaired—Melphalan—ovarian cancer	0.000501	0.0788	CcSEcCtD
Methamphetamine—ADRA2C—lymph node—ovarian cancer	0.000485	0.00547	CbGeAlD
Methamphetamine—CYP2D6—female gonad—ovarian cancer	0.000467	0.00526	CbGeAlD
Methamphetamine—SLC22A5—lymph node—ovarian cancer	0.000465	0.00524	CbGeAlD
Methamphetamine—CYP2D6—testis—ovarian cancer	0.000414	0.00466	CbGeAlD
Methamphetamine—ADRA2A—lymph node—ovarian cancer	0.000387	0.00436	CbGeAlD
Methamphetamine—Dizziness—Altretamine—ovarian cancer	0.000255	0.0401	CcSEcCtD
Methamphetamine—Tremor—Chlorambucil—ovarian cancer	0.000157	0.0248	CcSEcCtD
Methamphetamine—Agitation—Chlorambucil—ovarian cancer	0.000154	0.0243	CcSEcCtD
Methamphetamine—Selegiline—ABCB1—ovarian cancer	0.000137	0.117	CrCbGaD
Methamphetamine—Dyspepsia—Chlorambucil—ovarian cancer	0.000121	0.019	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Chlorambucil—ovarian cancer	0.000118	0.0186	CcSEcCtD
Methamphetamine—Tachycardia—Melphalan—ovarian cancer	0.000117	0.0183	CcSEcCtD
Methamphetamine—Palpitations—Vinorelbine—ovarian cancer	0.000113	0.0178	CcSEcCtD
Methamphetamine—Urticaria—Chlorambucil—ovarian cancer	0.000109	0.0171	CcSEcCtD
Methamphetamine—Dyspepsia—Topotecan—ovarian cancer	0.000107	0.0169	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Topotecan—ovarian cancer	0.000105	0.0166	CcSEcCtD
Methamphetamine—Dyspepsia—Melphalan—ovarian cancer	0.000105	0.0165	CcSEcCtD
Methamphetamine—Constipation—Topotecan—ovarian cancer	0.000104	0.0164	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Melphalan—ovarian cancer	0.000103	0.0162	CcSEcCtD
Methamphetamine—Tachycardia—Vinorelbine—ovarian cancer	0.000102	0.016	CcSEcCtD
Methamphetamine—Hypersensitivity—Chlorambucil—ovarian cancer	0.000101	0.0159	CcSEcCtD
Methamphetamine—Urticaria—Topotecan—ovarian cancer	9.69e-05	0.0153	CcSEcCtD
Methamphetamine—Urticaria—Melphalan—ovarian cancer	9.48e-05	0.0149	CcSEcCtD
Methamphetamine—Diarrhoea—Chlorambucil—ovarian cancer	9.37e-05	0.0148	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Vinorelbine—ovarian cancer	9e-05	0.0142	CcSEcCtD
Methamphetamine—Hypersensitivity—Topotecan—ovarian cancer	8.98e-05	0.0141	CcSEcCtD
Methamphetamine—Constipation—Vinorelbine—ovarian cancer	8.92e-05	0.014	CcSEcCtD
Methamphetamine—Hypersensitivity—Melphalan—ovarian cancer	8.8e-05	0.0139	CcSEcCtD
Methamphetamine—Diarrhoea—Topotecan—ovarian cancer	8.34e-05	0.0131	CcSEcCtD
Methamphetamine—Urticaria—Vinorelbine—ovarian cancer	8.29e-05	0.013	CcSEcCtD
Methamphetamine—Diarrhoea—Melphalan—ovarian cancer	8.17e-05	0.0129	CcSEcCtD
Methamphetamine—Dizziness—Topotecan—ovarian cancer	8.06e-05	0.0127	CcSEcCtD
Methamphetamine—Tremor—Paclitaxel—ovarian cancer	8.05e-05	0.0127	CcSEcCtD
Methamphetamine—Agitation—Paclitaxel—ovarian cancer	7.9e-05	0.0124	CcSEcCtD
Methamphetamine—Hypersensitivity—Vinorelbine—ovarian cancer	7.68e-05	0.0121	CcSEcCtD
Methamphetamine—Headache—Topotecan—ovarian cancer	7.64e-05	0.012	CcSEcCtD
Methamphetamine—Palpitations—Paclitaxel—ovarian cancer	7.6e-05	0.012	CcSEcCtD
Methamphetamine—Diarrhoea—Vinorelbine—ovarian cancer	7.14e-05	0.0112	CcSEcCtD
Methamphetamine—Dizziness—Vinorelbine—ovarian cancer	6.9e-05	0.0109	CcSEcCtD
Methamphetamine—Tachycardia—Paclitaxel—ovarian cancer	6.85e-05	0.0108	CcSEcCtD
Methamphetamine—Headache—Vinorelbine—ovarian cancer	6.53e-05	0.0103	CcSEcCtD
Methamphetamine—Palpitations—Docetaxel—ovarian cancer	6.44e-05	0.0101	CcSEcCtD
Methamphetamine—Insomnia—Paclitaxel—ovarian cancer	6.35e-05	0.00999	CcSEcCtD
Methamphetamine—Dyspepsia—Paclitaxel—ovarian cancer	6.18e-05	0.00972	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Paclitaxel—ovarian cancer	6.06e-05	0.00954	CcSEcCtD
Methamphetamine—Constipation—Paclitaxel—ovarian cancer	6e-05	0.00945	CcSEcCtD
Methamphetamine—Tachycardia—Docetaxel—ovarian cancer	5.8e-05	0.00914	CcSEcCtD
Methamphetamine—Urticaria—Paclitaxel—ovarian cancer	5.57e-05	0.00878	CcSEcCtD
Methamphetamine—Insomnia—Docetaxel—ovarian cancer	5.38e-05	0.00847	CcSEcCtD
Methamphetamine—Dyspepsia—Docetaxel—ovarian cancer	5.23e-05	0.00824	CcSEcCtD
Methamphetamine—Hypersensitivity—Paclitaxel—ovarian cancer	5.17e-05	0.00814	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Docetaxel—ovarian cancer	5.13e-05	0.00808	CcSEcCtD
Methamphetamine—Constipation—Docetaxel—ovarian cancer	5.09e-05	0.00801	CcSEcCtD
Methamphetamine—Diarrhoea—Paclitaxel—ovarian cancer	4.8e-05	0.00756	CcSEcCtD
Methamphetamine—Dizziness—Paclitaxel—ovarian cancer	4.64e-05	0.00731	CcSEcCtD
Methamphetamine—Agitation—Epirubicin—ovarian cancer	4.52e-05	0.00711	CcSEcCtD
Methamphetamine—Headache—Paclitaxel—ovarian cancer	4.39e-05	0.00692	CcSEcCtD
Methamphetamine—Hypersensitivity—Docetaxel—ovarian cancer	4.38e-05	0.0069	CcSEcCtD
Methamphetamine—Palpitations—Epirubicin—ovarian cancer	4.34e-05	0.00684	CcSEcCtD
Methamphetamine—Agitation—Doxorubicin—ovarian cancer	4.18e-05	0.00658	CcSEcCtD
Methamphetamine—Diarrhoea—Docetaxel—ovarian cancer	4.07e-05	0.00641	CcSEcCtD
Methamphetamine—Palpitations—Doxorubicin—ovarian cancer	4.02e-05	0.00633	CcSEcCtD
Methamphetamine—Dizziness—Docetaxel—ovarian cancer	3.93e-05	0.00619	CcSEcCtD
Methamphetamine—Tachycardia—Epirubicin—ovarian cancer	3.91e-05	0.00616	CcSEcCtD
Methamphetamine—Headache—Docetaxel—ovarian cancer	3.73e-05	0.00587	CcSEcCtD
Methamphetamine—Insomnia—Epirubicin—ovarian cancer	3.63e-05	0.00571	CcSEcCtD
Methamphetamine—Tachycardia—Doxorubicin—ovarian cancer	3.62e-05	0.0057	CcSEcCtD
Methamphetamine—Dyspepsia—Epirubicin—ovarian cancer	3.53e-05	0.00556	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Epirubicin—ovarian cancer	3.46e-05	0.00545	CcSEcCtD
Methamphetamine—Constipation—Epirubicin—ovarian cancer	3.43e-05	0.0054	CcSEcCtD
Methamphetamine—Insomnia—Doxorubicin—ovarian cancer	3.36e-05	0.00529	CcSEcCtD
Methamphetamine—Dyspepsia—Doxorubicin—ovarian cancer	3.27e-05	0.00514	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Doxorubicin—ovarian cancer	3.2e-05	0.00505	CcSEcCtD
Methamphetamine—Urticaria—Epirubicin—ovarian cancer	3.19e-05	0.00502	CcSEcCtD
Methamphetamine—Constipation—Doxorubicin—ovarian cancer	3.17e-05	0.005	CcSEcCtD
Methamphetamine—Hypersensitivity—Epirubicin—ovarian cancer	2.96e-05	0.00465	CcSEcCtD
Methamphetamine—Urticaria—Doxorubicin—ovarian cancer	2.95e-05	0.00464	CcSEcCtD
Methamphetamine—Diarrhoea—Epirubicin—ovarian cancer	2.74e-05	0.00432	CcSEcCtD
Methamphetamine—Hypersensitivity—Doxorubicin—ovarian cancer	2.73e-05	0.00431	CcSEcCtD
Methamphetamine—Dizziness—Epirubicin—ovarian cancer	2.65e-05	0.00418	CcSEcCtD
Methamphetamine—Diarrhoea—Doxorubicin—ovarian cancer	2.54e-05	0.004	CcSEcCtD
Methamphetamine—Headache—Epirubicin—ovarian cancer	2.51e-05	0.00396	CcSEcCtD
Methamphetamine—Dizziness—Doxorubicin—ovarian cancer	2.45e-05	0.00386	CcSEcCtD
Methamphetamine—Headache—Doxorubicin—ovarian cancer	2.32e-05	0.00366	CcSEcCtD
Methamphetamine—ADRA2B—Signaling by GPCR—PIK3CG—ovarian cancer	1.73e-05	0.000259	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—XIAP—ovarian cancer	1.73e-05	0.000258	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—FASN—ovarian cancer	1.72e-05	0.000256	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PPP2R1A—ovarian cancer	1.71e-05	0.000255	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—MAPK3—ovarian cancer	1.71e-05	0.000255	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—PIK3CB—ovarian cancer	1.7e-05	0.000253	CbGpPWpGaD
Methamphetamine—ADRA2A—Platelet activation, signaling and aggregation—AKT1—ovarian cancer	1.7e-05	0.000253	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—SLC5A5—ovarian cancer	1.69e-05	0.000252	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—VEGFA—ovarian cancer	1.69e-05	0.000252	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—IL6ST—ovarian cancer	1.69e-05	0.000252	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—SMARCA4—ovarian cancer	1.68e-05	0.000251	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—TP53—ovarian cancer	1.68e-05	0.000251	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—PIK3CD—ovarian cancer	1.68e-05	0.00025	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—NRAS—ovarian cancer	1.67e-05	0.000249	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—PIK3CD—ovarian cancer	1.65e-05	0.000246	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—EREG—ovarian cancer	1.64e-05	0.000245	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—SLC2A1—ovarian cancer	1.63e-05	0.000244	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—MAPK1—ovarian cancer	1.63e-05	0.000243	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—PIK3CG—ovarian cancer	1.62e-05	0.000242	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—IL2—ovarian cancer	1.61e-05	0.000241	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—HRAS—ovarian cancer	1.61e-05	0.00024	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—MAPK3—ovarian cancer	1.6e-05	0.000238	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—ABCB1—ovarian cancer	1.59e-05	0.000237	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—PIK3CD—ovarian cancer	1.57e-05	0.000234	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—CYP1B1—ovarian cancer	1.57e-05	0.000234	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—TYMS—ovarian cancer	1.56e-05	0.000233	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—IL6—ovarian cancer	1.54e-05	0.00023	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PGR—ovarian cancer	1.54e-05	0.00023	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—KRAS—ovarian cancer	1.54e-05	0.000229	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PPP2R1A—ovarian cancer	1.53e-05	0.000228	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—CAV1—ovarian cancer	1.53e-05	0.000228	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—PIK3CD—ovarian cancer	1.52e-05	0.000227	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—MAPK1—ovarian cancer	1.52e-05	0.000227	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—PTEN—ovarian cancer	1.47e-05	0.000219	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—PIK3CB—ovarian cancer	1.46e-05	0.000218	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—PIK3CG—ovarian cancer	1.45e-05	0.000216	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—PIK3CB—ovarian cancer	1.44e-05	0.000214	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—KRAS—ovarian cancer	1.44e-05	0.000214	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PARP1—ovarian cancer	1.43e-05	0.000214	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PPP2R1A—ovarian cancer	1.43e-05	0.000213	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—PIK3CD—ovarian cancer	1.42e-05	0.000212	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—AKT1—ovarian cancer	1.42e-05	0.000212	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—PIK3CA—ovarian cancer	1.41e-05	0.000211	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—CXCL8—ovarian cancer	1.41e-05	0.00021	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—PIK3CG—ovarian cancer	1.39e-05	0.000208	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PPP2R1A—ovarian cancer	1.39e-05	0.000207	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—YAP1—ovarian cancer	1.37e-05	0.000205	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—VEGFA—ovarian cancer	1.37e-05	0.000205	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—IL6ST—ovarian cancer	1.37e-05	0.000204	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—PIK3CB—ovarian cancer	1.37e-05	0.000204	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—TP53—ovarian cancer	1.37e-05	0.000204	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—NRAS—ovarian cancer	1.35e-05	0.000202	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—IL2—ovarian cancer	1.34e-05	0.0002	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—PIK3CB—ovarian cancer	1.33e-05	0.000198	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—PIK3CA—ovarian cancer	1.32e-05	0.000197	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—PIK3CG—ovarian cancer	1.32e-05	0.000196	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—CXCL8—ovarian cancer	1.31e-05	0.000196	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—HRAS—ovarian cancer	1.31e-05	0.000195	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—MAPK3—ovarian cancer	1.3e-05	0.000193	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—ABCB1—ovarian cancer	1.29e-05	0.000192	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—CXCL8—ovarian cancer	1.28e-05	0.00019	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—TP53—ovarian cancer	1.28e-05	0.00019	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—PIK3CD—ovarian cancer	1.27e-05	0.00019	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—TYMS—ovarian cancer	1.27e-05	0.000189	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—CAV1—ovarian cancer	1.26e-05	0.000187	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—IL2—ovarian cancer	1.26e-05	0.000187	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—PTEN—ovarian cancer	1.24e-05	0.000185	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—PIK3CB—ovarian cancer	1.24e-05	0.000185	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—MAPK1—ovarian cancer	1.23e-05	0.000184	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—PIK3CD—ovarian cancer	1.22e-05	0.000182	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—IL2—ovarian cancer	1.22e-05	0.000182	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—HRAS—ovarian cancer	1.22e-05	0.000182	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—TERT—ovarian cancer	1.22e-05	0.000181	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—CXCL8—ovarian cancer	1.19e-05	0.000178	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—KRAS—ovarian cancer	1.17e-05	0.000174	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PPP2R1A—ovarian cancer	1.16e-05	0.000173	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—PIK3CD—ovarian cancer	1.16e-05	0.000173	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—AKT1—ovarian cancer	1.15e-05	0.000172	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PIK3CG—ovarian cancer	1.14e-05	0.000171	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—IL2—ovarian cancer	1.14e-05	0.00017	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TERT—ovarian cancer	1.14e-05	0.000169	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CAV1—ovarian cancer	1.12e-05	0.000168	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—FASN—ovarian cancer	1.12e-05	0.000167	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—PIK3CB—ovarian cancer	1.11e-05	0.000166	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—SLC5A5—ovarian cancer	1.1e-05	0.000164	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—ESR1—ovarian cancer	1.08e-05	0.000162	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—AKT1—ovarian cancer	1.08e-05	0.000161	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—PIK3CA—ovarian cancer	1.07e-05	0.00016	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—CXCL8—ovarian cancer	1.07e-05	0.000159	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IL6ST—ovarian cancer	1.07e-05	0.000159	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—PIK3CB—ovarian cancer	1.07e-05	0.000159	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—SLC2A1—ovarian cancer	1.06e-05	0.000159	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CAV1—ovarian cancer	1.05e-05	0.000157	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—TP53—ovarian cancer	1.04e-05	0.000155	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—PIK3CA—ovarian cancer	1.04e-05	0.000155	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PIK3CG—ovarian cancer	1.02e-05	0.000153	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—APC—ovarian cancer	1.02e-05	0.000153	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—NRAS—ovarian cancer	1.02e-05	0.000153	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—CAV1—ovarian cancer	1.02e-05	0.000152	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CYP1B1—ovarian cancer	1.02e-05	0.000152	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—IL2—ovarian cancer	1.02e-05	0.000152	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—ESR1—ovarian cancer	1.01e-05	0.000151	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—PIK3CB—ovarian cancer	1.01e-05	0.00015	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PIK3CD—ovarian cancer	1.01e-05	0.00015	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IL6ST—ovarian cancer	9.96e-06	0.000149	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—HRAS—ovarian cancer	9.91e-06	0.000148	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—MAPK3—ovarian cancer	9.81e-06	0.000146	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—CXCL8—ovarian cancer	9.69e-06	0.000145	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PIK3CG—ovarian cancer	9.57e-06	0.000143	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—APC—ovarian cancer	9.57e-06	0.000143	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—NRAS—ovarian cancer	9.57e-06	0.000143	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—MAPK1—ovarian cancer	9.34e-06	0.000139	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—EGFR—ovarian cancer	9.33e-06	0.000139	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PIK3CG—ovarian cancer	9.3e-06	0.000139	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—IL2—ovarian cancer	9.26e-06	0.000138	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TERT—ovarian cancer	9.23e-06	0.000138	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—PTEN—ovarian cancer	9.21e-06	0.000137	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—MAPK3—ovarian cancer	9.17e-06	0.000137	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	9.05e-06	0.000135	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PIK3CD—ovarian cancer	9.01e-06	0.000134	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—PIK3CA—ovarian cancer	8.92e-06	0.000133	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—KRAS—ovarian cancer	8.82e-06	0.000132	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PIK3CB—ovarian cancer	8.77e-06	0.000131	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—PIK3CA—ovarian cancer	8.76e-06	0.000131	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—AKT1—ovarian cancer	8.75e-06	0.000131	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—MAPK1—ovarian cancer	8.72e-06	0.00013	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—EGFR—ovarian cancer	8.72e-06	0.00013	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CAV1—ovarian cancer	8.53e-06	0.000127	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—AKT1—ovarian cancer	8.46e-06	0.000126	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PIK3CD—ovarian cancer	8.41e-06	0.000125	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—ABCB1—ovarian cancer	8.4e-06	0.000125	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—PIK3CA—ovarian cancer	8.33e-06	0.000124	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—TYMS—ovarian cancer	8.25e-06	0.000123	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—KRAS—ovarian cancer	8.24e-06	0.000123	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—ESR1—ovarian cancer	8.22e-06	0.000123	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PIK3CD—ovarian cancer	8.17e-06	0.000122	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—PIK3CA—ovarian cancer	8.1e-06	0.000121	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IL6ST—ovarian cancer	8.09e-06	0.000121	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—ERBB2—ovarian cancer	7.96e-06	0.000119	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MTOR—ovarian cancer	7.85e-06	0.000117	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PIK3CB—ovarian cancer	7.85e-06	0.000117	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—APC—ovarian cancer	7.77e-06	0.000116	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PIK3CG—ovarian cancer	7.77e-06	0.000116	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—NRAS—ovarian cancer	7.77e-06	0.000116	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PTEN—ovarian cancer	7.58e-06	0.000113	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—PIK3CA—ovarian cancer	7.57e-06	0.000113	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CXCL8—ovarian cancer	7.54e-06	0.000113	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—HRAS—ovarian cancer	7.5e-06	0.000112	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—MAPK3—ovarian cancer	7.44e-06	0.000111	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—ERBB2—ovarian cancer	7.43e-06	0.000111	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CDKN1B—ovarian cancer	7.37e-06	0.00011	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PIK3CB—ovarian cancer	7.33e-06	0.000109	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MTOR—ovarian cancer	7.33e-06	0.000109	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—AKT1—ovarian cancer	7.29e-06	0.000109	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CASP3—ovarian cancer	7.22e-06	0.000108	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IL2—ovarian cancer	7.21e-06	0.000108	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—IL6—ovarian cancer	7.17e-06	0.000107	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—AKT1—ovarian cancer	7.16e-06	0.000107	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PIK3CB—ovarian cancer	7.12e-06	0.000106	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—MAPK1—ovarian cancer	7.08e-06	0.000106	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—EGFR—ovarian cancer	7.08e-06	0.000106	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CXCL8—ovarian cancer	7.05e-06	0.000105	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CCND1—ovarian cancer	7.03e-06	0.000105	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—HRAS—ovarian cancer	7e-06	0.000104	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CTNNB1—ovarian cancer	6.96e-06	0.000104	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CDKN1B—ovarian cancer	6.88e-06	0.000103	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PIK3CD—ovarian cancer	6.83e-06	0.000102	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MMP9—ovarian cancer	6.82e-06	0.000102	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—AKT1—ovarian cancer	6.81e-06	0.000102	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PTEN—ovarian cancer	6.78e-06	0.000101	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—PIK3CA—ovarian cancer	6.77e-06	0.000101	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CASP3—ovarian cancer	6.74e-06	0.000101	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IL2—ovarian cancer	6.73e-06	0.0001	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—IL6—ovarian cancer	6.7e-06	0.0001	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—KRAS—ovarian cancer	6.69e-06	9.98e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CAV1—ovarian cancer	6.65e-06	9.92e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—AKT1—ovarian cancer	6.62e-06	9.87e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CCND1—ovarian cancer	6.57e-06	9.79e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CTNNB1—ovarian cancer	6.5e-06	9.7e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—PIK3CA—ovarian cancer	6.5e-06	9.7e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MMP9—ovarian cancer	6.37e-06	9.51e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PTEN—ovarian cancer	6.34e-06	9.45e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—AKT1—ovarian cancer	6.18e-06	9.22e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PTEN—ovarian cancer	6.16e-06	9.18e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—PIK3CA—ovarian cancer	6.15e-06	9.17e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—VEGFA—ovarian cancer	6.13e-06	9.14e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—STAT3—ovarian cancer	6.07e-06	9.05e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PIK3CG—ovarian cancer	6.06e-06	9.04e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—NRAS—ovarian cancer	6.05e-06	9.03e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—ERBB2—ovarian cancer	6.04e-06	9e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MTOR—ovarian cancer	5.96e-06	8.88e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PIK3CB—ovarian cancer	5.96e-06	8.88e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MAPK3—ovarian cancer	5.8e-06	8.65e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CXCL8—ovarian cancer	5.72e-06	8.54e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—VEGFA—ovarian cancer	5.72e-06	8.54e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—HRAS—ovarian cancer	5.69e-06	8.48e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—STAT3—ovarian cancer	5.67e-06	8.45e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—NRAS—ovarian cancer	5.65e-06	8.43e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MYC—ovarian cancer	5.64e-06	8.41e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CDKN1B—ovarian cancer	5.59e-06	8.34e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—AKT1—ovarian cancer	5.53e-06	8.25e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MAPK1—ovarian cancer	5.52e-06	8.23e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—EGFR—ovarian cancer	5.51e-06	8.23e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CASP3—ovarian cancer	5.48e-06	8.17e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IL2—ovarian cancer	5.47e-06	8.16e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—IL6—ovarian cancer	5.44e-06	8.12e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MAPK3—ovarian cancer	5.41e-06	8.08e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PIK3CA—ovarian cancer	5.35e-06	7.97e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CCND1—ovarian cancer	5.33e-06	7.95e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PIK3CD—ovarian cancer	5.33e-06	7.94e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—AKT1—ovarian cancer	5.31e-06	7.92e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CTNNB1—ovarian cancer	5.28e-06	7.88e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MYC—ovarian cancer	5.27e-06	7.86e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—KRAS—ovarian cancer	5.21e-06	7.77e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MMP9—ovarian cancer	5.18e-06	7.72e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MAPK1—ovarian cancer	5.15e-06	7.68e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—EGFR—ovarian cancer	5.15e-06	7.68e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PTEN—ovarian cancer	5.15e-06	7.68e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—AKT1—ovarian cancer	5.02e-06	7.49e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—KRAS—ovarian cancer	4.87e-06	7.26e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PIK3CA—ovarian cancer	4.79e-06	7.14e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—VEGFA—ovarian cancer	4.65e-06	6.93e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PIK3CB—ovarian cancer	4.64e-06	6.92e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—TP53—ovarian cancer	4.63e-06	6.91e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—STAT3—ovarian cancer	4.6e-06	6.87e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—NRAS—ovarian cancer	4.59e-06	6.85e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PIK3CA—ovarian cancer	4.47e-06	6.67e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—HRAS—ovarian cancer	4.43e-06	6.6e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MAPK3—ovarian cancer	4.4e-06	6.56e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—AKT1—ovarian cancer	4.37e-06	6.51e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PIK3CA—ovarian cancer	4.34e-06	6.48e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TP53—ovarian cancer	4.32e-06	6.45e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MYC—ovarian cancer	4.28e-06	6.38e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IL6—ovarian cancer	4.24e-06	6.32e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MAPK1—ovarian cancer	4.18e-06	6.24e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—EGFR—ovarian cancer	4.18e-06	6.24e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—HRAS—ovarian cancer	4.14e-06	6.17e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PTEN—ovarian cancer	4.01e-06	5.98e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IL6—ovarian cancer	3.96e-06	5.9e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—KRAS—ovarian cancer	3.95e-06	5.9e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—AKT1—ovarian cancer	3.91e-06	5.83e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—AKT1—ovarian cancer	3.65e-06	5.45e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PIK3CA—ovarian cancer	3.63e-06	5.42e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—AKT1—ovarian cancer	3.55e-06	5.29e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TP53—ovarian cancer	3.51e-06	5.24e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—HRAS—ovarian cancer	3.36e-06	5.01e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IL6—ovarian cancer	3.22e-06	4.8e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—AKT1—ovarian cancer	2.97e-06	4.42e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PIK3CA—ovarian cancer	2.83e-06	4.22e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—AKT1—ovarian cancer	2.31e-06	3.45e-05	CbGpPWpGaD
